Genetics of ectopia lentis

Seminars in Ophthalmology

Volumn 28, Issue 5-6, 2013, Pages 313-320

  Sadiq, Mohammad Ali ^a   Vanderveen, Deborah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Ehler Danlos; Homocystinuria; Marfan; Subluxated lens; Sulfite oxidase deficiency; Weill marchesani

Indexed keywords

ARTICLE; ECTOPIA LENTIS; ECTOPIA LENTIS ET PUPILLAE; ECTOPIA LENTIS SIMPLEX; EHLERS DANLOS SYNDROME; ENZYME DEFICIENCY; GENETICS; HOMOCYSTINURIA; MARFAN SYNDROME; PRIORITY JOURNAL; SULFITE OXIDASE DEFICIENCY; WEILL MARCHESANI SYNDROME;

ECTOPIA LENTIS; HUMANS; MUTATION;

EID: 84886376585     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.825276     Document Type: Article

References (75)

1. Anteby I, Isaac M, BenEzra D. Hereditary subluxated lenses: visual performances and long-term follow-up after surgery. Ophthalmology 2003;110(7):1344-1348.
2. Rasooly R, Benezra D. Unilateral lens dislocation and axial elongation in Marfan syndrome. Ophthalmic Paediatr Genet 1988;9(2):135-136.
3. Callewaert B, Malfait F, Loeys B, De Paepe A. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol 2008;22(1):165-189.
4. Grahame R, Pyeritz RE. The Marfan syndrome: joint and skin manifestations are prevalent and correlated. Br J Rheumatol 1995;34(2):126-131.
5. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47(7):476-485.
6. Maumenee IH. The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 1981;79:684-733.
7. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989; 64(8):507-512.
8. Pyeritz RE, Wappel MA. Mitral valve dysfunction in the Marfan syndrome: clinical and echocardiographic study of prevalence and natural history. Am J Med 1983; 74(5):797-807.
9. Fattori R, Nienaber CA, Descovich B, et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet 1999;354(9182):910-913.
10. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352(6333):337-339.
11. Micheal S, Khan MI, Akhtar F, et al. Identification of a novel FBN1 gene mutation in a large Pakistani family with Marfan syndrome. Mol Vis 2012;18:1918-1926.
12. Ammash NM, Sundt TM, Connolly HM. Marfan syndrome-diagnosis and management. Curr Probl Cardiol 2008; 33(1):7-39.
13. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to patho-genesis in Marfan syndrome. Nat Genet 2003;33(3):407-411.
14. Ades LC, Sullivan K, Biggin A, et al. FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited. American Journal of Medical Genetics 2006; 140(10):1047-1058.
15. Robinson PN, Booms P, Katzke S, et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002; 20(3):153-161.
16. Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. American Journal of Human Genetics 2007;81(3):454-466.
17. Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006;43(10):769-787.
18. Rommel K, Karck M, Haverich A, et al. Identification of 29 novel and nine recurrent fibrillin-1 (FBN1) mutations and genotype-phenotype correlations in 76 patients with Marfan syndrome. Hum Mutat 2005;26(6):529-539.
19. Spaeth GL, Barber GW. Homocystinuria in a mentally retarded child and her normal cousin. Trans Am Acad Ophthalmol Otolaryngol 1965;69(5):912-930.
20. Gerritsen T, Waisman HA. Homocystinuria, an error in the metabolism of methionine. Pediatrics 1964;33:413-420.
21. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. American Journal of Human Genetics 1985;37(1):1-31.
22. Barber GW, Spaeth GL. The successful treatment of homo-cystinuria with pyridoxine. J Pediatr 1969;75(3):463-478.
23. Hubmacher D, Cirulis JT, Miao M, et al. Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. J Biol Chem 2010; 285(2):1188-1198.
24. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid Redox Signal 2006;8(3-4): 338-346.
25. Martinez-Gutierrez JD, Mencia-Gutierrez E, Gracia-Garcia-Miguel T, et al. Classical familial homocystinuria in an adult presenting as an isolated lens subluxation. Int Ophthalmol 2011;31(3):227-232.
26. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metab 2010;99(1):1-3.
27. Skovby F, Kraus JP, Rosenberg LE. Homocystinuria: biogenesis of cystathionine beta-synthase subunits in cultured fibroblasts and in an in vitro translation system programmed with fibroblast messenger RNA. American Journal of Human Genetics 1984;36(2):452-459.
28. Taoka S, Widjaja L, Banerjee R. Assignment of enzymatic functions to specific regions of the PLP-dependent heme protein cystathionine beta-synthase. Biochemistry 1999; 38(40):13155-13161.
29. Munke M, Kraus JP, Ohura T, Francke U. The gene for cystathionine beta-synthase (CBS) maps to the subtelo-meric region on human chromosome 21q and to proximal mouse chromosome 17. American Journal of Human Genetics 1988;42(4):550-559.
30. Kozich V, Sokolova J, Klatovska V, et al. Cystathionine beta-synthase mutations: effect of mutation topology on folding and activity. Hum Mutat 2010;31(7):809-819.
31. Sokolova J, Janosikova B, Terwilliger JD, et al. Cystathionine beta-synthase deficiency in Central Europe: discrepancy between biochemical and molecular genetic screening for homocystinuric alleles. Hum Mutat 2001; 18(6):548-549.
32. Gallagher PM, Ward P, Tan S, et al. High frequency (71%) of cystathionine beta-synthase mutation G307S in Irish homocystinuria patients. Hum Mutat 1995;6(2): 177-180.
33. Urreizti R, Asteggiano C, Bermudez M, et al. The p.T191M mutation of the CBS gene is highly prevalent among homocystinuric patients from Spain, Portugal and South America. J Hum Genet 2006;51(4):305-313.
34. De Lucca M, Casique L. Characterization of cystathionine beta-synthase gene mutations in homocystinuric Venezuelan patients: identification of one novel mutation in exon 6. Mol Genet Metab 2004;81(3):209-215.
35. Kruger WD, Wang L, Jhee KH, et al. Cystathionine beta-synthase deficiency in Georgia (USA): correlation of clinical and biochemical phenotype with genotype. Hum Mutat 2003;22(6):434-441.
36. Lee SJ, Lee DH, Yoo HW, et al. Identification and functional analysis of cystathionine beta-synthase gene mutations in patients with homocystinuria. J Hum Genet 2005; 50(12):648-654.
37. Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. Hematology Am Soc Hematol Educ Program 2003:62-81.
38. Kim CE, Gallagher PM, Guttormsen AB, et al. Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria. Hum Mol Genet 1997; 6(13):2213-2221.
39. Faivre L, Dollfus H, Lyonnet S, et al. Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome. American Journal of Medical Genetics 2003; 123A(2):204-207.
40. TM [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013.
41. Hubmacher D, Apte SS. Genetic and functional linkage between ADAMTS superfamily proteins and fibrillin-1: a novel mechanism influencing microfibril assembly and function. Cell Mol Life Sci 2011;68(19):3137-3148.
42. Kutz WE, Wang LW, Dagoneau N, et al. Functional analysis of an ADAMTS10 signal peptide mutation in Weill-Marchesani syndrome demonstrates a long-range effect on secretion of the full-length enzyme. Hum Mutat 2008;29(12):1425-1434.
43. Evereklioglu C, Hepsen IF, Er H. Weill-Marchesani syndrome in three generations. Eye (Lond) 1999;13(Pt 6): 773-777.
44. Wirtz MK, Samples JR, Kramer PL, et al. Weill-Marchesani syndrome: possible linkage of the autosomal dominant form to 15q21.1. Am J Med Genet 1996;65(1):68-75.
45. Kloepfer HW, Rosenthal JW. Possible genetic carriers in the spherophakia-brachymorphia syndrome. American Journal of Human Genetics 1955;7(4):398-425.
46. Faivre L, Megarbane A, Alswaid A, et al. Homozygosity mapping of a Weill-Marchesani syndrome locus to chromosome 19p13.3-p13.2. Hum Genet 2002; 110(4):366-370.
47. Faivre L, Gorlin RJ, Wirtz MK, et al. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet 2003;40(1):34-36.
48. Morales J, Al-Sharif L, Khalil DS, et al. Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. American Journal of Human Genetics 2009; 85(5):558-568.
49. Kutz WE, Wang LW, Bader HL, et al. ADAMTS10 protein 780 interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. J Biol Chem 2011;286(19):17156-17167.
50. Le Goff C, Morice-Picard F, Dagoneau N, et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet 2008;40(9):1119-1123.
51. Malfait F, Coucke P, Symoens S, et al. The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. Hum Mutat 2005;25(1):28-37.
52. Schalkwijk J, Zweers MC, Steijlen PM, et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001;345(16):1167-1175.
53. Schwarze U, Hata R, McKusick VA, et al. Rare auto-somal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. American Journal of Human Genetics 2004;74(5): 917-930.
54. Makareeva E, Cabral WA, Marini JC, Leikin S. Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. J Biol Chem 2006;281(10):6463-6470.
55. Colige A, Nuytinck L, Hausser I, et al. Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol 2004; 123(4):656-663.
56. Woody NC. Hyperlysinemia. Am J Dis Child 1964;108: 543-553.
57. Ozalp I, Hasanoglu A, Tuncbilek E, Yalaz K. Hyperlysinemia without clinical findings. Acta Paediatr Scand 1981;70(6):951-953.
58. Dancis J, Hutzler J, Cox RP, Woody NC. Familial hyperlysinemia with lysine-ketoglutarate reductase insufficiency. J Clin Invest 1969;48(8):1447- 1452.
59. Bhattacharjee JK. alpha-Aminoadipate pathway for the biosynthesis of lysine in lower eukaryotes. Crit Rev Microbiol 1985;12(2):131-151.
60. Sacksteder KA, Biery BJ, Morrell JC, et al. Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia. American Journal of Human Genetics 2000;66(6):1736-1743.
61. Mudd SH, Irreverre F, Laster L. Sulfite oxidase deficiency in man: demonstration of the enzymatic defect. Science 1967;156(3782):1599-1602.
62. Tan WH, Eichler FS, Hoda S, et al. Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature. Pediatrics 2005;116(3):757-766.
63. Dublin AB, Hald JK, Wootton-Gorges SL. Isolated sulfite oxidase deficiency: MR imaging features. AJNR Am J Neuroradiol 2002;23(3):484-485.
64. Schiaffino MC, Fantasia AR, Minniti G, et al. Isolated sulphite oxidase deficiency: clinical and biochemical features in an Italian patient. J Inherit Metab Dis 2004; 27(1):101-102.
65. Sachdev NH, Coroneo MT, Wakefield D, Hennessy MP. Isolated ectopia lentis: potential role of matrix metallopro-teinases in fibrillin degradation. Arch Ophthalmol 2004; 122(1):111-114.
66. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477(1-2):267-283.
67. Lee HF, Mak BS, Chi CS, et al. A novel mutation in neonatal isolated sulphite oxidase deficiency. Neuropediatrics 2002;33(4):174-179.
68. Johnson JL, Rajagopalan KV, Renier WO, et al. Isolated sulfite oxidase deficiency: mutation analysis and DNA-based prenatal diagnosis. Prenatal Diagnosis 2002; 22(5):433-436.
69. Rupar CA, Gillett J, Gordon BA, et al. Isolated sulfite oxidase deficiency. Neuropediatrics 1996;27(6):299-304.
70. Al-Salem M. Autosomal recessive ectopia lentis in two Arab family pedigrees. Ophthalmic Paediatr Genet 1990; 11(2):123-127.
71. Goldberg MF. Clinical manifestations of ectopia lentis et pupillae in 16 patients. Ophthalmology 1988;95(8): 1080-1087.
72. Luebbers JA, Goldberg MF, Herbst R, et al. Iris transillu-mination and variable expression in ectopia lentis et pupillae. Am J Ophthalmol 1977;83(5):647-656.
73. Kainulainen K, Karttunen L, Puhakka L, et al. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat Genet 1994;6(1):64-69.
74. Lonnqvist L, Child A, Kainulainen K, et al. A novel mutation of the fibrillin gene causing ectopia lentis. Genomics 1994;19(3):573-576.
75. Ades LC, Holman KJ, Brett MS, et al. Ectopia lentis phenotypes and the FBN1 gene. American Journal of Medical Genetics 2004;126A(3):284-289.